Anticoagulation and Th rombembolism During Bevacizumab Treatment – To Be Careful or Fearful?

Autor:	Andrea Jurečková, Pochop L, Jiří Tomášek, Jana Halámková, Adámková Krákorová D, S Tuček
Rok vydání:	2015
Předmět:	medicine.medical_specialty genetic structures Bevacizumab business.industry Angiogenesis Anticoagulants Angiogenesis Inhibitors Surgery Oncology Thromboembolism Concomitant medicine Humans Angiogenesis Inhibition Intensive care medicine business medicine.drug
Zdroj:	Klinicka onkologie. 28:293-295
ISSN:	1802-5307 0862-495X
Popis:	Inhibition of angiogenesis is a valid approach in today's medicine. Besides oncology, it is used in ophthalmology, as well. In oncology, angiogenesis inhibition has become a routine and accessible method. A combination of angiogenesis inhibition and other therapies, including anticoagulation and antiaggregation is common in many cases. Bevacizumab is the most used antiangiogenic agent and has been in use for the longest period of time. A concomitant administration of angiogenesis inhibitors and anticoagulation may be feared by oncologists. From the available literature it is obvious that concomitant administration of bevacizumab and anticoagulation is safe. Also, use of antiaggregation and bevacizumab is safe. The risk of venous and arterial thromboembolism is real during the treatment with bevacizumab. Therefore, concomitant anticoagulation is not only possible but also may be desirable.
Databáze:	OpenAIRE
Externí odkaz:	https://explore.openaire.eu/search/publication?articleId=doi_dedup___::fd043780a89798403523c0259433f11a https://doi.org/10.14735/amko2015293 Zobrazit plný text záznamu